CD123与CD47在急性髓细胞白血病干细胞中的表达及临床意义

目的探讨CD123与CD47在急性髓细胞白血病（AML）干细胞中的表达，及其与临床预后的关系。方法纳入2009年3月至2015年8月急性髓细胞白血病患者127例（AML组），并纳入23例健康体检者作为对照组。采用流式细胞仪检测骨髓干细胞内的CD123与CD47表达，观察不同患者两种标记物的表达，并分析两种标记物阳性表达与患者疗效和预后的关系。结果CD47在各种亚型患者干细胞中的表达差异无统计学意义（P〉0．05）。CD47高表达患者90例，常规治疗后完全缓解率（CR）低，白血病发病率高。CD123在不同类型的患者中表达程度存在一定差异，AML组CD123阳性表达率为63．0％，远高于健康对照17．4％，其阳性表达患者临床预后较差。结论CD123与CD47可作为判断急性白血病预后的诊断指标。

Objective To investigate the expression of CD 123 and CD47 in the leukemia stem cells in patients with acute myelocytic leukemia （ AML ） , as well as the correlation between their expression Of clinical prognosis. Methods One hundred and twenty-seven AML patients admitted to our hospital from March 2009 to August 2015 were included in this study. Besides, twenty-three healthy individuals received physical examination in our hospital served as control. CD123 and CD47 expression was determined using flow cytometry. In addition, the correlation between their expression and the clinical prognosis was evaluated. Results No difference was noticed in the expression of CD47 in the subtypes of AML patients. CD47 expression was noticed in 90 patients, which showed poor clinical outcome after chemotherapy. Whereas, for the patients with positive expression of CD123, statistical difference was observed in the patients with various subtypes. Higher positive rate of CD 123 was observed in AML patients compared to the normal control. Conclusions CD123 and CD47 could be used as predictors for the prognosis of AML patients.